By Josh White
Date: Thursday 29 Feb 2024
(Sharecast News) - Oncimmune reported revenue of £2.1m in its final results on Thursday, down from £3.8m for the prior extended 15-month period, with revenue from continuing operations totalling £1.2m.
By Josh White
Date: Monday 22 May 2023
(Sharecast News) - Immunodiagnostics specialist Oncimmune announced the sale of its wholly-owned subsidiaries Oncimmune Limited and Oncimmune Europe to the US-based, privately-held Freenome Holdings on Monday.
By Josh White
Date: Friday 17 Feb 2023
(Sharecast News) - Immunodiagnostics specialist Oncimmune announced a collaboration with Siemens Healthineers on Friday, to improve malignancy risk assessment of indeterminate pulmonary nodules (IPNs).
Currency | UK Pounds |
Share Price | 19.70p |
Change Today | -4.80p |
% Change | -19.59 % |
52 Week High | 29.10 |
52 Week Low | 15.10 |
Volume | 147,940 |
Shares Issued | 74.14m |
Market Cap | £14.61m |
Value |
---|
Price Trend |
---|
Income |
---|
Growth |
---|
No dividends found |
Time | Volume / Share Price |
16:27 | 11,883 @ 19.24p |
14:47 | 9,187 @ 19.26p |
14:44 | 6,751 @ 20.13p |
14:41 | 10,000 @ 20.80p |
14:41 | 2,158 @ 20.96p |
You are here: research